Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.

Diabet Med. 2013 Jul;30(7):846-54. doi: 10.1111/dme.12158. Epub 2013 Mar 29.

PMID:
23413771
2.

A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.

Diabetes Technol Ther. 2013 Mar;15(3):214-22. doi: 10.1089/dia.2012.0272. Epub 2013 Feb 21.

PMID:
23427864
3.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
4.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Res Clin Pract. 2012 Oct;98(1):51-60. doi: 10.1016/j.diabres.2012.05.022. Epub 2012 Jun 9.

PMID:
22682949
5.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
6.

A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.

Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.

Expert Opin Pharmacother. 2012 Dec;13(17):2433-42. doi: 10.1517/14656566.2012.730519. Epub 2012 Oct 15.

PMID:
23061989
7.

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.

Alba M, Ahrén B, Inzucchi SE, Guan Y, Mallick M, Xu L, O'Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2013 Dec;15(12):1101-10. doi: 10.1111/dom.12145. Epub 2013 Jul 19.

PMID:
23782502
9.
10.

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Jan;14(1):67-76. doi: 10.1111/j.1463-1326.2011.01492.x. Epub 2011 Nov 3.

PMID:
22050786
11.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
12.

Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.

Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.

Intern Med. 2013;52(19):2179-87. Epub 2012 Mar 1.

13.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
14.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group.

Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9. Epub 2010 Jun 26.

PMID:
20580422
15.

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

Pérez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ.

Int J Clin Pract. 2011 Sep;65(9):930-8. doi: 10.1111/j.1742-1241.2011.02749.x.

PMID:
21849007
16.

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.

Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S.

J Intern Med. 2006 Aug;260(2):125-33.

17.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
18.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H.

Int J Clin Pract. 2011 Feb;65(2):154-64. doi: 10.1111/j.1742-1241.2010.02589.x.

PMID:
21235696
19.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.

PMID:
17130197
20.

Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):12-5.

PMID:
18354861

Supplemental Content

Support Center